Sign In
Buy CLLS
$2.75
-0.100 (-3.51%)
At Close: Jul 31, 2026
Cellectis Reports Financial Results for First Quarter 2024
04:30pm, Tuesday, 28'th May 2024
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 2024 1 ; cash runway projection into 2026 2 •
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
04:30pm, Monday, 27'th May 2024
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to de
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
02:00am, Monday, 06'th May 2024
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
04:30pm, Thursday, 02'nd May 2024
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
04:46pm, Monday, 29'th Apr 2024
• Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
04:30pm, Monday, 22'nd Apr 2024
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseases Non-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
04:30pm, Wednesday, 10'th Apr 2024
Cellectis publishes an approach that could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
04:30pm, Friday, 22'nd Dec 2023
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving
Cellectis' Shareholders Meeting to be Held on December 22, 2023
04:30pm, Friday, 17'th Nov 2023
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
02:30am, Wednesday, 15'th Nov 2023
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that, following the consultation of its works council, it has now signed a binding Subs
Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript
02:22pm, Tuesday, 07'th Nov 2023
Cellectis SA (NASDAQ:CLLS ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-founder, CEO& Director Mark Frat
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
04:30pm, Monday, 06'th Nov 2023
• Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase
Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects
06:57pm, Friday, 03'rd Nov 2023
Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia.
